Sign In
Buy PDS
$95.01
+1.95 (+2.10%)
At Close: Jun 03, 2026
Precision Drilling Corporation Announces Filing of Annual Disclosure Documents
04:45pm, Monday, 10'th Mar 2025
CALGARY, Alberta, March 10, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) announces that it has filed its annual disclosure documents with the securities commissions in each of t
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
08:45am, Friday, 07'th Mar 2025
First-ever HPV16-positive head and neck cancer Phase 3 clinical trial First-ever HPV16-positive head and neck cancer Phase 3 clinical trial
EMV Capital portfolio company PDS Biotechnology raises $11mln
03:34am, Friday, 28'th Feb 2025
EMV Capital plc (AIM: EMVC) portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) has raised $11 million, through an equity funding. PDS, which is focussed on immunotherapies, sold around 7.3
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:00am, Thursday, 27'th Feb 2025
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkp
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
08:00am, Monday, 24'th Feb 2025
Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025
Precision Drilling: Accelerating Capital Returns Should Put A Floor On The Stock
07:17pm, Thursday, 20'th Feb 2025
Precision Drilling Corporation underwhelmed in its Q4-2024 report. The company did deliver on its debt reduction target and cash flow should start flowing increasingly in the direction of shareholders
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
08:00am, Thursday, 20'th Feb 2025
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
Precision Drilling Corporation (PDS) Q4 2024 Earnings Call Transcript
05:49pm, Thursday, 13'th Feb 2025
Precision Drilling Corporation (NYSE:PDS ) Q4 2024 Earnings Conference Call February 13, 2025 1:00 PM ET Company Participants Lavonne Zdunich - VP, Investor Relations Carey Ford - CFO Kevin Neveu - Pr
Precision Drilling (PDS) Misses Q4 Earnings and Revenue Estimates
09:11pm, Wednesday, 12'th Feb 2025
Precision Drilling (PDS) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $1.40 per share. This compares to earnings of $3.45 per share a year ago.
Precision Drilling Announces 2024 Fourth Quarter and Year End Unaudited Financial Results
06:45pm, Wednesday, 12'th Feb 2025
CALGARY, Alberta, Feb. 12, 2025 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure
Precision Drilling Corporation 2024 Fourth Quarter and Year-End Results Conference Call and Webcast
04:00pm, Tuesday, 14'th Jan 2025
CALGARY, Alberta, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2024 fourth quarter and year-end results after the market closes on Wednesday, Feb
This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and th
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 06'th Dec 2024
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET
08:00am, Tuesday, 03'rd Dec 2024
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation Discussion topics to include pathology and prev
